Tag Archives: peritoneal mesothelioma

National Institutes of Health Reports on Advances in Malignant Peritoneal Mesothelioma

National Institutes of Health Reports on Advances in Malignant Peritoneal Mesothelioma

A new article from the National Institutes of Health gives the latest advances in mesothelioma. CRS-HIPEC has offered improved survival for surgical candidates. But outcomes for inoperable malignant peritoneal mesothelioma remain poor. Advancements in technology have provided new treatment approaches. The NIH reports new clinical trials are arising and are imperative. The Numbers Behind Peritoneal Mesothelioma Peritoneal mesothelioma is caused by exposure to asbestos. It is caused by the ingestion of asbestos fibers. Those microscopic asbestos fibers become embedded in the abdomen (peritoneum). After 20 to 50 years, these fibers can cause inflammation and mutations in the healthy mesothelial cells. These mutations can cause these cells to become cancerous thus, forming tumors in the peritoneum. Patients diagnosed with peritoneal mesothelioma … Continue reading National Institutes of Health Reports on Advances in Malignant Peritoneal Mesothelioma »

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma

Peritoneal mesothelioma is caused by asbestos. The peritoneum is the space in your abdomen that contains the intestines, the stomach, and the liver. The abdomen (peritoneum) is the second most common site of mesothelioma after the pleural (lungs and chest). Most doctors believe peritoneal mesothelioma is caused by the ingestion of asbestos fibers. Microscopic asbestos fibers become embedded in the abdomen (peritoneum). After about 20-50 years, these fibers can cause inflammation and mutations in the healthy mesothelial cells. These mutations may ultimately cause these cells to become cancerous. Thus, forming tumors in the peritoneum. Patients diagnosed with peritoneal mesothelioma may survive several or more years after diagnosis. There are long-term survivors, such as Paul Kraus. Using CT Scans to Avoid … Continue reading Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma »

Korean Cancer Doctors Embrace PIPAC for Mesothelioma

PIPAC for mesothelioma

Five out of ten Korean oncologists surveyed feel positive about using an aerosolized chemotherapy system called PIPAC for mesothelioma and other types of cancer. PIPAC stands for pressurized intraperitoneal aerosol chemotherapy. The system turns liquid chemotherapy drugs into a spray that can be applied with a nebulizer. It was developed to treat surface malignancies like peritoneal mesothelioma that can be hard to treat with standard methods.  PIPAC can be used in conjunction with mesothelioma surgery or by itself as either a palliative or curative treatment.  The technology is still very new. Many doctors have never used it. But research conducted by the Seoul National University College of Medicine shows Korean doctors are ready to embrace it. How Spray-on Chemotherapy Works … Continue reading Korean Cancer Doctors Embrace PIPAC for Mesothelioma »

Misdiagnosis of Mesothelioma More Common with Cytology Alone

misdiagnosis of mesothelioma

A new set of case reports illustrates how easily misdiagnosis of mesothelioma can happen when the diagnosis is based on cytology alone.  Cytology tests look at the cells in body fluids. For peritoneal mesothelioma patients, this is often the fluid that collects in their abdomen called ascites.  But doctors from India’s Dayanand Medical College and Hospital say using ascites samples alone to diagnose mesothelioma is a risky practice. Misdiagnosis of mesothelioma may delay proper treatment and negatively impact survival. The Difficulty of Diagnosing Peritoneal Mesothelioma Malignant mesothelioma only impacts about 2,500 people in the US every year. It is most common among people who have lived or worked around asbestos. Peritoneal mesothelioma is even rarer. About a fifth of patients … Continue reading Misdiagnosis of Mesothelioma More Common with Cytology Alone »

New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival

long-term peritoneal mesothelioma survival

One of the nation’s top mesothelioma doctors says long-term peritoneal mesothelioma survival is possible with a far-reaching new surgical technique. Dr. Paul Sugarbaker is a surgeon with the Washington Cancer Institute in Washington, DC. He has studied peritoneal mesothelioma for decades.  In a new report, he outlines a case of long-term peritoneal mesothelioma survival in a female patient. The patient had cytoreductive surgery. The surgery included resection of the colonic mesentery. This is tissue that is not normally part of peritoneal mesothelioma surgery.  The case report shows the patient is still cancer-free four years after surgery with an “excellent” quality of life.  The Challenge of Peritoneal Mesothelioma Every year, about 2,500 Americans receive a diagnosis of mesothelioma. Peritoneal mesothelioma accounts … Continue reading New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival »

New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma

immunotherapy for peritoneal meosthelioma

A new study from one of the nation’s top cancer centers supports the role of immunotherapy in peritoneal mesothelioma treatment. Immunotherapy is a treatment approach that aims to harness the body’s natural defense system to fight cancer.  Several immunotherapy drugs have been tested for pleural mesothelioma. Pleural mesothelioma affects the lungs. Last year, the FDA approved a new combination of immunotherapy drugs for the pleural form of asbestos cancer.  But there is less data on immunotherapy for peritoneal mesothelioma. Researchers at MD Anderson Cancer Center just released their findings on a class of immunotherapy drugs called immune checkpoint inhibitors (ICIs). They say it is the first “real-world evidence” of clinical outcomes with ICIs in peritoneal mesothelioma patients. Immune Checkpoint Inhibitors … Continue reading New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma »

Peritoneal Mesothelioma Prognosis: Searching for New Factors

peritoneal mesothelioma prognosis

An international research study including patients from 11 countries may help reveal new and better ways to predict peritoneal mesothelioma prognosis.  Right now, doctors use three primary criteria to determine peritoneal mesothelioma prognosis. Those are how much cancer was in the abdomen at the time of surgery, how complete the surgery was, and the tumor grade.  But about 70 percent of people treated for peritoneal cancers like mesothelioma have recurrent disease. The goal of the new study is to find more prognostic factors. Knowing these factors could help doctors make better choices about which patients are most likely to benefit from cytoreductive surgery (CRS).  The CRS/HIPEC Procedure for Mesothelioma Peritoneal mesothelioma occurs on the lining of the abdomen. Peritoneal mesothelioma … Continue reading Peritoneal Mesothelioma Prognosis: Searching for New Factors »

Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People

metastatic peritoneal mesothelioma

Administering the chemotherapy drug paclitaxel directly into the abdomen of people with mesothelioma might offer a way to prevent metastatic peritoneal mesothelioma. That is the premise of a recent article by Dr. Paul Sugarbaker in the Journal of Gastrointestinal Oncology. Dr. Sugarbaker is a global expert in peritoneal mesothelioma. He works at MedStar Washington Hospital in Washington, DC. Metastatic peritoneal mesothelioma is when mesothelioma cells spread. They move from their original spot to other parts of the abdomen. Paclitaxel can help prevent new tumors in people who already have some metastases. In his new article, Dr. Sugarbaker says the evidence suggests that it might also work to keep metastases from forming. Metastatic Peritoneal Mesothelioma Treatment Malignant mesothelioma is a cancer … Continue reading Paclitaxel May Prevent Metastatic Peritoneal Mesothelioma in High Risk People »

NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival?

nipec treatment

A mesothelioma treatment called NIPEC may help people with peritoneal mesothelioma live longer than expected. In some cases, much longer. A recent study of 74 peritoneal mesothelioma patients showed a combination of cytoreductive surgery (CRS), HIPEC, and NIPEC works better than CRS/HIPEC alone. The study comes from one of the country’s foremost medical authorities on peritoneal mesothelioma. Dr. Paul Sugarbaker runs the Peritoneal Surface Malignancy Program at Washington Cancer Institute in Washington, DC.  Last year, Dr. Sugarbaker released results of a small study on NIPEC treatment for mesothelioma. Although that study included only six patients, the results were impressive enough to warrant further study.  This year’s larger NIPEC study is even more promising for people fighting mesothelioma. Similarities and DIfferences … Continue reading NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival? »

Concerning CT Findings and Mesothelioma Prognosis

Concerning CT Findings

One of the nation’s top mesothelioma doctors says concerning CT findings may be one of the best ways to predict peritoneal mesothelioma outcomes.  Dr. Paul Sugarbaker is with MedStar Washington Hospital Center in Washington, DC. His newly published study compares 11 different concerning CT findings with outcomes in 100 mesothelioma patients.  Sugarbaker and his team found that the prognostic value of these 11 CT features is on a par with peritoneal cancer index (PCI) and cytoreduction (CC) score. It means that CT findings could become even more important for mesothelioma treatment planning.  CT Scans Reveal Information About Peritoneal Mesothelioma Peritoneal mesothelioma occurs on the lining around the abdomen. It is an aggressive and hard-to-treat cancer caused by exposure to asbestos. … Continue reading Concerning CT Findings and Mesothelioma Prognosis »